AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales

Key TakeawaysAstraZeneca's second-quarter earnings beat expectations Thursday, and the drugmaker also lifted its guidance.Like its COVID-19 vaccine manufacturing colleagues Pfizer and Johnson & Johnson, AstraZeneca's revenue from vaccines fell year-over-year.During the quarter, the company said at its annual investor day that it believes the drugs in its development pipeline can boost revenue to $80 billion annually by 2030, compared to $45 billion in 2023. AstraZeneca (AZN) posted better-than-expected resu ...